@kmartfit's TRT dosing claims need more context
Quick answer
The creator discloses a personal TRT protocol of 180mg testosterone per week split into two injections, reporting total testosterone levels of 950-1,000 ng/dL. This sits at the upper boundary of the AUA's clinical target range and is above the median dose used in most TRT trials, though individual pharmacokinetics vary considerably. The content lacks any reference to lab monitoring, hematocrit tracking, or cardiovascular screening, which are standard components of ongoing TRT management.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @kmartfit actually say?
He's been on doctor-prescribed TRT for over three years, takes 180mg of testosterone per week, splits it into two injections for blood level stability, and says his total testosterone runs between 950 and 1,000 ng/dL. He feels "freaking amazing" and is pointing followers toward online TRT resources via a comment-funnel. That's the full picture. No product names, no injection instructions, just a personal protocol disclosure and a lead-gen hook.
Does the science back this up?
Partially. The split-dosing rationale is solid. The testosterone level he's targeting sits at the high end of what most clinicians would consider acceptable, but it's not outside the range of published practice.
Splitting a weekly testosterone cypionate or enanthate dose into two injections does reduce peak-to-trough fluctuation. A 2020 study by Ramasamy et al. in Urology confirmed that more frequent dosing intervals correlate with more stable serum levels and fewer side effects tied to supraphysiologic peaks. That part checks out.
The 950-1,000 ng/dL target is trickier. The American Urological Association's 2018 guidelines set the target range for TRT at roughly 400-700 ng/dL for most men, with some clinicians accepting up to 1,000 ng/dL. His stated levels sit at the ceiling of that range, not the center. That's not automatically dangerous, but it's worth flagging.
What did they get wrong (or right)?
Let's give credit where it's due: split dosing is genuinely better than once-weekly injections for stability, and he's being transparent about his numbers rather than vague-posting. That's more than most TRT content on this platform offers.
What's missing is context about why 180mg lands him at 950-1,000 ng/dL. Testosterone response varies considerably between individuals based on SHBG levels, conversion rates, and injection site. Someone watching this who starts 180mg expecting identical results could end up at 1,400 ng/dL or 600 ng/dL. Presenting a personal dose without that disclaimer is where the content gets quietly misleading.
The comment-funnel to "online resources" is also worth scrutinizing. Directing followers to unspecified online TRT services without any mention of baseline labs, cardiovascular screening, or hematocrit monitoring is an incomplete picture of what responsible TRT initiation looks like.
What should you actually know?
Testosterone replacement therapy is a legitimate, FDA-approved treatment for clinically diagnosed hypogonadism, defined as total testosterone below roughly 300 ng/dL combined with symptoms. It is not a general wellness upgrade for men who feel tired or want more muscle.
Before anyone starts TRT, labs should include total and free testosterone, LH, FSH, hematocrit, PSA, and a lipid panel at minimum. A 2017 review by Bhasin et al. in the New England Journal of Medicine outlined that erythrocytosis (elevated red blood cell count) is one of the most common adverse effects of injectable testosterone, particularly at higher doses and less frequent intervals. Monitoring hematocrit every three to six months matters.
Cardiovascular risk remains an open debate. The 2023 TRAVERSE trial published in the New England Journal of Medicine found no significant increase in major cardiovascular events in men on TRT versus placebo over about 33 months, which was reassuring but not a blanket green light for all patients.
Is this content safe to act on?
As personal disclosure, it's mostly fine. As a blueprint for starting TRT, it has real gaps. The dose he mentions is above average for replacement therapy. His target testosterone level is at the upper boundary of clinical guidelines. And the call to action, "comment TRT and I'll send you resources," offers no context about whether those resources involve actual diagnostic workups or just telehealth prescription services that skip the hard parts.
If you're exploring TRT, the right starting point is a full hormone panel from a licensed provider, not a comment thread. What works for a 3-year veteran with established labs and physician oversight is not a template for someone who has never had their testosterone measured.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 6 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For @kmartfit's TRT dosing claims need more context, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Cardiovascular Safety of Testosterone-Replacement Therapy
TRAVERSE trial anchor for cardiovascular-safety discussions in appropriately diagnosed men.
PubMed
Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline
Guideline anchor for diagnosis, monitoring, contraindications, and appropriate TRT framing.
PubMed
NAD+ metabolism and its roles in cellular processes during ageing
Core review for NAD+ decline, mitochondrial function, DNA repair, and aging biology.
PubMed
Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women
Human NMN source for metabolic claims while keeping population limits clear.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
@kmartfit's TRT dosing claims need more context is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Claim path
Keep researching this testosterone and trt video claims cluster
Best for searchers turning TRT social claims into a safer lab-backed provider discussion.
Claim verdict
The useful answer behind this video
Claim being checked
The creator discloses a personal TRT protocol of 180mg testosterone per week split into two injections, reporting total testosterone levels of 950-1,000 ng/dL.
FormBlends verdict
The creator discloses a personal TRT protocol of 180mg testosterone per week split into two injections, reporting total testosterone levels of 950-1,000 ng/dL. This sits at the upper boundary of the AUA's clinical target range and is above the median dose used in most TRT trials, though individual pharmacokinetics vary considerably. The content lacks any reference to lab monitoring, hematocrit tracking, or cardiovascular screening, which are standard components of ongoing TRT management.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator discloses a personal TRT protocol of 180mg testosterone per week split into two injections, reporting total testosterone levels of 950-1,000 ng/dL. This sits at the upper boundary of the AUA's clinical target range and is above the median dose used in most TRT trials, though individual pharmacokinetics vary considerably. The content lacks any reference to lab monitoring, hematocrit tracking, or cardiovascular screening, which are standard components of ongoing TRT management.
- AUA 2018 guidelines target 400-700 ng/dL for most TRT patients; 950-1,000 ng/dL is at the upper boundary of clinical acceptability, not the typical goal
- Twice-weekly injection of testosterone cypionate or enanthate is evidence-supported for reducing serum level fluctuation, per Ramasamy et al. (2020, Urology)
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- AUA 2018 guidelines target 400-700 ng/dL for most TRT patients; 950-1,000 ng/dL is at the upper boundary of clinical acceptability, not the typical goal
- Twice-weekly injection of testosterone cypionate or enanthate is evidence-supported for reducing serum level fluctuation, per Ramasamy et al. (2020, Urology)
- 180mg per week is above the commonly studied replacement dose range of 75-100mg per week; individual response varies enough that this dose could produce very different results in another person
- The 2023 TRAVERSE trial (New England Journal of Medicine) found no significant increase in major cardiovascular events on TRT versus placebo over 33 months, but this was in a specific patient population with cardiovascular risk factors, not a blanket safety endorsement
- Erythrocytosis is the most common adverse effect of injectable testosterone therapy; hematocrit should be monitored every 3-6 months, a fact absent from this content
- Clinically diagnosed hypogonadism requires total testosterone below approximately 300 ng/dL plus symptoms; TRT is not indicated solely for optimization in men with normal baseline levels
- Any online TRT service that does not require baseline labs including total testosterone, LH, FSH, hematocrit, PSA, and a lipid panel before prescribing is not following standard clinical practice
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
KMART · TikTok creator
7.9K views on this video
My dose of TRT
Not medical advice. This video was made by KMART, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.